While combination anti-PD-1 and anti-CTLA-4 therapy has been shown to be clinically effective against various tumor types, the high incidence of developing immune-related adverse events, such as colitis, limits widespread use, particularly in older patients with multiple medical comorbidities (18). This evidence concerns the gene PDCD1 and neoplasm.